A controlled study of combined methotrexate, BCG, and INH therapy for squamous cell carcinoma of the head and neck

Surg Clin North Am. 1977 Aug;57(4):769-78. doi: 10.1016/s0039-6109(16)41287-9.

Abstract

In a randomized prospective study of patients with advanced squamous cell carcinoma of the head and neck, treatment with MTX plus BCG and with MTX plus BCG plus INH produced no better response rate or survival time than treatment with MTX alone.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • BCG Vaccine / administration & dosage
  • BCG Vaccine / therapeutic use*
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / immunology
  • Carcinoma, Squamous Cell / mortality
  • Cyclophosphamide / administration & dosage
  • Drug Therapy, Combination
  • Female
  • Head and Neck Neoplasms / drug therapy*
  • Head and Neck Neoplasms / immunology
  • Head and Neck Neoplasms / mortality
  • Humans
  • Hypersensitivity, Delayed / immunology
  • Isoniazid / administration & dosage
  • Isoniazid / therapeutic use*
  • Male
  • Methotrexate / administration & dosage
  • Methotrexate / therapeutic use*
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Recurrence, Local / drug therapy

Substances

  • BCG Vaccine
  • Cyclophosphamide
  • Isoniazid
  • Methotrexate